Drug Profile
Pegipanermin - INmune Bio
Alternative Names: DN-TNF; INB-03; LIVNate™; Quellor™; Soluble tumour necrosis factor inhibitor; XENP1595; XENP345; XPro 1595; XPro595; XProTMLatest Information Update: 06 Feb 2024
Price :
$50
*
At a glance
- Originator Emory University; Xencor
- Developer Alzheimer's Association; Emory University; FPRT Bio; INmune Bio; Xencor
- Class Anti-inflammatories; Antidementias; Antidepressants; Antineoplastics; Antiparkinsonians; Hepatoprotectants; Polyethylene glycols; Recombinant proteins
- Mechanism of Action Immunostimulants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alzheimer's disease; Major depressive disorder; Mild cognitive impairment
- Preclinical HER2 positive breast cancer
- No development reported Neurodegenerative disorders; Non-alcoholic steatohepatitis; Solid tumours
- Discontinued COVID-19 respiratory infection; Parkinson's disease
Most Recent Events
- 30 Jan 2024 INmune Bio plans an end-of-phase II meeting with US FDA for planned global Phase III trial in Alzheimer's disease in early 2025
- 30 Jan 2024 The US FDA lifts the full clinical hold on the Alzheimer's disease clinical trial program
- 30 Jan 2024 INmune Bio plans a global phase III trial for Alzheimer's disease in the US, Canada, the UK, the European Union and Pacific Rim